Sports
Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial
CagriSema achieved superior weight loss of up to 14.2%, where up to 43% of the people achieved ≥15% weight loss and up to 24% achieved ≥20% weight loss1.CagriSema achieved superior HbA1c reduction of up to 1.91%-points1 from a mean HbA1c baseline of 8.2%.Superiority was established on both weight loss and HbA1c versus the individual components.In the trial, CagriSema appeared to have a safe and well-tolerated profile consistent with incretin and amylin-based therapies. Bagsværd, Denmark, 2 Febru
About this update from Novo Nordisk A/s Class B
[{"type":"image","alt":"Novo Nordisk A/S","displaySize":"","headline":null,"caption":"Novo Nordisk A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":214,"url":"https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Sq36MpNFOiz.w6RiXrpsqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e","width":300,"height":214}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"CagriSema achieved superior weight loss of up to 14.2%, where up to 43% of the people achieved ≥15% weight loss and up to 24% achieved ≥20% weight loss1.","length":153,"tagName":"p"}]},{"val":[{"type":"text","content":"CagriSema achieved superior HbA1c reduction of up to 1.91%-points1 from a mean HbA1c baseline of 8.2%.","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"Superiority was established on both weight loss and HbA1c versus the individual components.","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"In the trial, CagriSema appeared to have a safe and well-tolerated profile consistent with incretin and amylin-based therapies.","length":127,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":473,"olType":false},{"type":"text","content":"Bagsværd, Denmark, 2 February 2026 – Novo Nordisk today announced headline results from REIMAGINE 2, a phase 3 trial from the global REIMAGINE clinical trial programme. CagriSema demonstrated both superior HbA1c reduction and weight loss at week 68 versus semaglutide, across all tested doses in the trial.","length":306,"tagName":"p"},{"type":"text","content":"REIMAGINE 2 was a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of the amylin receptor agonist, cagrilintide, and the GLP-1 receptor agonist, semaglutide) in two different doses (2.4 mg/2.4 mg and 1.0 mg/1.0 mg) compared to two different doses of semaglutide (2.4 mg and 1.0 mg), cagrilintide (2.4 mg), and placebo. The trial included 2,728 people with type 2 diabetes inadequately controlled with metformin with or without an SGLT2 inhibitor. Approximately 40% of all people were using an SGLT2 inhibitor before initiating the trial.","length":597,"tagName":"p"},{"type":"text","content":"When e...